Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct 6:4:1244609.
doi: 10.3389/fpain.2023.1244609. eCollection 2023.

Case report: Chronic pain in a pediatric patient with late-onset pompe disease

Affiliations
Case Reports

Case report: Chronic pain in a pediatric patient with late-onset pompe disease

Amanda Cao et al. Front Pain Res (Lausanne). .

Abstract

Pompe disease (PD) is a rare inherited metabolic disorder of deficient or absent acid alpha-glucosidase (GAA), resulting in defective lysosomal glycogen catabolism. Muscle weakness, respiratory deficiency and gastrointestinal symptoms are commonly monitored in PD. However, pain and associated psychological symptoms are less focused upon. A pediatric patient with late-onset Pompe disease (LOPD) comorbid with chronic pain is presented. Symptoms of pain in the feet were first reported between 6 and 7 years of age and were attributed to growing pains. Following progression of lower body pain, weakness, fatigue, and difficulties with ambulation, a thorough clinical assessment including genetic testing was performed, which led to a diagnosis of LOPD at 9 years of age. ERT with recombinant human alglucosidase alfa was subsequently started. The patient's clinical status is compounded by depressed mood, anxiety, and attention deficit hyperactivity disorder, which may further exacerbate pain. A multidisciplinary pain treatment approach consisting of orthopedics, physical therapy, and psychosocial therapy aimed at enhancing pain coping skills is described for this LOPD patient. This case highlights the need for a greater understanding of pain generation and identification of optimized pain treatment approaches in children with LOPD that can be implemented alongside ERT.

Keywords: ADHD; analgesia; depression; lysosomal storage disease; pain; pompe disease.

PubMed Disclaimer

Conflict of interest statement

JU and WA receive funding support from SanofiGenzyme. WA is a site Principal Investigator for the Early Access Program with Arimoclomol in US Patients with NPC (NCT04316637), which is sponsored by KemPharm Denmark A/S WA is on the advisory board for Beam Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Clinical history and timeline.
Figure 2
Figure 2
Evaluation of psychological and physical factors: (A) the patient shows higher level of depression, stress, anxiety, and sleep disturbances, and reduced quality of peer relationships, physical functioning, cognitive functioning, and mobility compared to the general population when assessed by patient-reported outcomes measurement information system (PROMIS) questionnaires. (B) On the NIH Toolbox Cognition Battery, the Total Composite Score and Early Childhood Composite scores factor in the Fluid Composite and Crystalized Composite Score to assess general cognitive function. For NIH Toolbox, T scores were corrected for gender, age, ethnicity, and education level. (C) Assessment of motor functioning utilizing the NIH Toolbox Motor Battery, evaluating dominant and nondominant function where accessible. On the 4 m Walk Gait Test, the patient scored (0.98 m/s) slightly below the age and gender-corrected mean (1.05 m/s).

Similar articles

References

    1. Reuser AJJ, Hirschhorn R, Kroos MA. Pompe disease: glycogen storage disease type II, acid α-glucosidase (acid maltase) deficiency. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The online metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill Education; (2019).
    1. Bhengu L, Davidson A, du Toit PJ, Els C, Gerntholtz T, Govendrageloo K, et al. Diagnosis and management of pompe disease. S Afr Med J. (2014) 104(4):273–4. 10.7196/samj.7386 - DOI - PubMed
    1. Kohler L, Puertollano R, Raben N. Pompe disease: from basic science to therapy. Neurotherapeutics. (2018) 15(4):928–42. 10.1007/s13311-018-0655-y - DOI - PMC - PubMed
    1. DeRuisseau LR, Fuller DD, Qiu K, DeRuisseau KC, Donnelly WH, Jr., Mah C, et al. Neural deficits contribute to respiratory insufficiency in pompe disease. Proc Natl Acad Sci U S A. 2009;106(23):9419–24. 10.1073/pnas.0902534106 - DOI - PMC - PubMed
    1. Mancall EL, Aponte GE, Berry RG. Pompe’s disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol. (1965) 24:85–96. 10.1097/00005072-196501000-00008 - DOI - PubMed

Publication types